Dr. Brunke has over 30 years of scientific, operational, clinical, senior executive, and corporate development managerial experience with large and small biotechnology/pharma companies. She is currently the Executive Vice President of Corporate and Business Development at Jaguar Health, Inc. (NASDAQ: JAGX) and Acting CEO of Magdalena Biosciences. She is also on the BOD of Cytodyn, Inc, a public company. Previously, Dr. Brunke was part of the executive team that merged Mercator Genetics Inc. with Progenitor, a subsidiary of Interneuron Pharmaceuticals, in 1999, and helped take the resulting company public. Dr. Brunke was Chief Operating Officer of Anexus Pharmaceuticals, a subsidiary of the Japanese public company MediBic, responsible for in- and out-licensing assistance for Japanese companies, and was founding Chief Executive Officer of Cardeus Pharmaceuticals, a neuroscience company. At Sandoz (11 years in research), her last position was Research Director as well as member of the global R&D committee, overseeing a department whose successes included recombinant insect-resistant plants (GMOs), an important backbone for the greater than $3 B annual seed business of the now Syngenta Seeds, with many billions of dollars of GMOs sold to date.